the Effect Between Platelet Reactivation and Antiplatelet Drugs
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes. Compared with clopidogrel, Ticagrelor is more powerful antiplatelet drug. However, because of increased bleeding and dyspnea risk, both loading double dose and following second dose time had potential risk and inconvenient in routine clinical work, especially in elective PCI of comparable stable patients in Chinese. The benefit and risk should be balanced in such patients. The investigators supposed loading single dose and followed by second routine time dose was superior to clopidogrel and safer than ticagrelor previously prescribed.
Drug Effect Disorder
Platelet Procoagulant Activity Deficiency
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Target Follow-Up Duration:||1 Year|
|Official Title:||Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.|
- Platelet reactivity [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]LTA and TEG used to measure the effect of Platelet reactivity
Biospecimen Retention: Samples Without DNA
|Study Start Date:||May 2014|
|Estimated Study Completion Date:||January 2015|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
All admission patients were divided into two groups, the first group were prescribed loading dose (180 mg) ticagrelor, the second group were prescribed with 90 mg ticagrelor. We measured both platelet activity and platelet reactivity using the LTA at baseline, pre-operation and post-operation. All bleeding or dyspnea events were recorded in hospital period.
Primary endpoints: platelet activity, platelet reactivity using the LTA and safety events were recorded in hospital period.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02198053
|Beijing, China, 100029|
|Study Director:||LI QUAN, doctor||Beijing Anzhen Hospital, Capital Medical University|